NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

Review Proposal Project

NICE Technology Appraisal no. 115; naltrexone for the management of opioid dependence

Provisional matrix of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
Manufacturers/sponsors	General
AOP Orphan Pharmaceuticals	Board of Community Health Councils in
(naltrexone)	Wales
Bristol-Myers Squibb (naltrexone)	British National Formulary
	Care Quality Commission
Patient/carer groups	Commissioning Support Appraisals
Addaction	Service
Adfam	Department of Health, Social Services
Afiya Trust	and Public Safety for Northern Ireland
Alliance	HM Prison Service
Black Health Agency	Medicines and Healthcare products
Chinese National Healthy Living	Regulatory Agency
Centre	National Association of Primary Care
Counsel and Care	National Treatment Agency for
 Equalities National Council 	Substance Misuse (NTA)
 Families Anonymous UK 	NHS Alliance
Lifeline	NHS Commercial Medicines Unit
 Muslim Council of Britain 	NHS Confederation
 Muslim Health Network 	NHS Quality Improvement Scotland
 Rehabilitation for Addicted Prisoners 	Public Health Wales NHS Trust
Trust (RAPt)	Scottish Medicines Consortium
Release	
 South Asian Health Foundation 	Comparator manufacturers
Specialised Healthcare Alliance	• none
Turning Point	
	Relevant research groups
Professional groups	Action on Addiction
Addiction Recovery Foundation	Centre for Research on Drugs and
Association of Nurses in Substance	Health Behaviour (Imperial College)
Abuse	Department of Addictive Behaviour and Discrete Addictive (Ct. Course)
British Association for	Pyschological Medicine (St George's
Psychopharmacology	Hospital Medical School)
British Association for Services to the	DrugScope Independent Drug Menitoring Unit
Elderly	Independent Drug Monitoring Unit (IDMI)
British Geriatrics Society	(IDMU) • MRC Clinical Trials Unit
European Association for the Transport of Addition LVC	
Treatment of Addiction UK	National Addiction Centre (Institute of

National Institute for Health and Clinical Excellence

NICE Technology Appraisal no. 115; naltrexone for managing opioid dependence

Issue date: August 2010

Consultees	Commentators (no right to submit or appeal)
 Federation of Drug and Alcohol Professionals National Drug Prevention Alliance National Pharmaceutical Association Pharmaceutical Services Negotiating Committee Royal College of General Practitioners Royal College of Nursing Royal College of Physicians Royal College of Psychiatrists (Addictions Faculty) Royal Pharmaceutical Society Royal Society of Medicine Specialist Clinical Addiction Network (SCAN) Substance Misuse Management in General Practice (SMMGP) United Kingdom Clinical Pharmacy Association UK Harm Reduction Alliance 	 Psychiatry) National Institute for Health Research Policy Research Institute on Ageing and Ethnicity Research Institute for the Care of Older People Society for the Study of Addiction Assessment Group National Institute for Health Research (NIHR) Health Technology Assessment Programme tbc Associated Guideline Groups National Collaborating Centre for Mental Health Associated Public Health Groups none
<u>Others</u>	
Department of Health NHS Brighton and Hove	
NHS Brighton and HoveNHS Bristol	
Welsh Assembly Government	

NICE is committed to promoting equality and eliminating unlawful discrimination.

Please let us know if we have missed any important organisations from the lists contained within the matrix and which organisations we should include who have a particular focus on relevant equality issues.

Definitions:

Consultees

Organisations that accept an invitation to participate in the appraisal; the manufacturer(s) or sponsor(s) of the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Assembly Government and relevant NHS organisations in England.

Consultees can participate in the consultation on the draft scope, the Assessment Report and the Appraisal Consultation Document, they are invited to prepare a submission dossier and all non-manufacturers/sponsors consultee organisations can nominate clinical specialists and patient experts to present their personal views to the Appraisal Committee. All consultees are given the opportunity to appeal against the Final Appraisal Determination (FAD).

Commentators

Organisations that engage in the appraisal process but that are not asked to prepare a submission dossier, and that receive the FAD for information only, without right of appeal. These organisations are: manufacturers of comparator technologies; NHS Quality Improvement Scotland; the relevant National Collaborating Centre (a group commissioned by the Institute to develop clinical guidelines); other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Information Authority and NHS Purchasing and Supplies Agency, and the *British National Formulary*.

All non-manufacturers/sponsors commentator organisations can nominate clinical specialists and patient experts to present their personal views to the Appraisal Committee.

Assessment team

An independent academic group (commissioned by the National Institute for Health Research (NIHR) Health Technology Assessment Programme (HTA Programme) to assist in the appraisal) prepares an Assessment Report on the health technology (a review of the clinical and cost effectiveness of the technology(ies) based on a systematic review of the literature and a review of manufacturer and sponsor submission to the Institute).

¹ Non manufacturer consultees are invited to submit statements relevant to the group they are representing.